Phase 3 Clinical Trials With Primary Completion Dates in February 2019

This is a list of Phase 3 trials with primary completion dates in February 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AIMT Aimmune Therapeutics, Inc. 2019-02-01 Phase 3 NCT03337542 AR101 Real-World Open-Label Extension Study
AIMT Aimmune Therapeutics, Inc. 2019-02-01 Phase 3 NCT03201003 ARTEMIS Peanut Allergy In Children
ALNY Alnylam Pharmaceuticals, Inc. 2019-02-01 Phase 3 NCT03338816 ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
ITCI Intra-Cellular Therapies Inc. 2019-02-01 Phase 3 NCT02600507 Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
MCRB Seres Therapeutics, Inc. 2019-02-01 Phase 3 NCT03183128 ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
MESO Mesoblast Limited 2019-02-01 Phase 3 NCT01233960 Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
PBYI Puma Biotechnology Inc 2019-02-01 Phase 3 NCT01808573 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
PRAH PRA Health Sciences, Inc. 2019-02-01 Phase 3 NCT01550003 Pediatric Arthritis Study of Certolizumab Pegol
PRTO Proteon Therapeutics, Inc. 2019-02-01 Phase 3 NCT02414841 A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
TCDA Tricida, Inc. 2019-02-01 Phase 3 NCT03390842 Long-term Safety Extension to Study TRCA-301
URGN UroGen Pharma Ltd. 2019-02-01 Phase 3 NCT02793128 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study